Cereno Scientific participates at the upcoming medical conference ACC.24 to further build presence in the Cardiology community
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for common and rare cardiovascular disease, today announced presence at ACC’s 73rd Annual Scientific Session & Expo (ACC.24) organized by the American College of Cardiology. The event is held between April 6–8, 2024 in Atlanta, Georgia, USA.
“Participating at leading cardiology congresses, such as ACC.24, is an important aspect of our strategy to continue to raise awareness about our portfolio of innovative drug candidates, learn about the most recent advances and expand our network among academic and industry actors. We will also take the opportunity while in Atlanta, to meet with members of our Scientific Advisory Board as well as members of the Clinical Steering Committee for our Phase II trial of CS1 in PAH to discuss the progress of our development programs as well as the upcoming finalization of the Phase II study,” said Sten R. Sörensen, CEO, Cereno Scientific.
From Cereno Sten R. Sörensen, Chief Executive Officer, Dr. Rahul Agrawal, Chief Medical Officer and Head of R&D, Dr. Björn Dahlöf, Chief Scientific Officer and Fredrik Frick, Head of Clinical Operations will participate.
ACC.24, 73rd Annual Scientific Session & Expo organized by the American College of Cardiology stands as the foremost cardiology conference in the Americas, attracting a substantial part of the cardiovascular care community. The American College of Cardiology is the professional home for more than 54,000 cardiovascular professionals from around the world. The ACC leads in the formation of health policy, standards and guidelines, and operates national registries to measure and improve care. It also provides professional medical education, disseminates cardiovascular research through its renowned JACC Journals, and bestows credentials upon cardiovascular specialists who meet stringent qualifications.
For further information, please contact:
Henrik Westdahl, Director IR & Communications
Email: henrik.westdahl@cerenoscientific.com
Phone: +46 70-817 59 96
Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific develops innovative treatments for common and rare cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q3 2024. Since January 2024, we are delighted that the FDA´s Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.